Clinical Trial

SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes

Study acronym: SBIIIvR
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Cerebral oximetry monitoring allows clinicians to optimize blood flow to the brain and oxygenation using the SafeBoosC treatment guideline. The guideline's interventions aims to stabilize blood pressure and oxygen levels. As low blood pressure is a risk factor for the development of kidney injury, normalizing blood pressure may decrease the incidence of kidney injury in new-borns who are on ventilator.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-11.
Trial Details
NCT Number NCT06926946
Lead Sponsor St. John's Research Institute
Collaborators: Rigshospitalet, Denmark
Conditions Acute Renal Failure, Neonatal Morbidity
Enrollment 1,000 participants
Start Date 2025-07-31
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-23